← board
CRON
distress 1/10 · well-funded / low risk$2.79+0%today-15% from 52w high
Revenue
$45M
Liquidity
$822M
Runway
—
Shares 1y
-2%
Price & events
+3.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
+1.3%
1W
+3.5%
1M
+7.1%
3M
+0.2%
6M
+33.3%
1Y
+11.8%
2Y
-61.0%
5Y
-63.4%
All
Overview
- Market Cap
- $1.04B
- Volume
- 78.64K
- 52 Week Range
- $1.95 – $3.27
- Total Shares
- 373.66M
- Float Shares
- 192.24M
- Short %
- 1.67%
- % Held by Insiders
- 48.55%
- % Held by Institutions
- 15.64%
- RVOL
- 0.09x
- Beta
- 1.24
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-12-09partnershipAcquisition of CanAdelaar B.V. for EUR 57.5M plus earn-outsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $3 (-10% upside) · 1 analysts
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-21Cronos Group Inc. - Baystreet.ca
- 2026-07-21Cronos Group Inc. - Baystreet.ca
- 2026-07-21Cronos’ SOURZ by Spinach® Expands its Lineup of Edibles - GlobeNewswire
- 2026-07-21Cronos’ SOURZ by Spinach® Expands its Lineup of Edibles - Yahoo Finance
- 2026-07-21Cronos’ SOURZ by Spinach® Expands its Lineup of Edibles - Toronto Star
- 2026-07-20Cannabis Stocks: Cronos Group (TSX:CRON) Reinforces Premium Positioning - Kalkine Media
- 2026-07-20Cronos Group (TSX:CRON) Expands Global Reach Beyond TSX Venture - Kalkine Media
- 2026-07-17Cronos Group Inc. stock rises Friday, outperforms market - MarketWatch
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.